The German “Biontech” and “Pfizer” companies announced on Wednesday that a joint project to produce a coronavirus vaccine has achieved positive initial results.
Preliminary data were recorded after a trial period on a vaccine against the emerging corona virus called 1/2, designed to demonstrate that the vaccine is non-toxic and activates an immune system response that prepares the body to fight the virus.
The experimental vaccine called BN162B1 produces counter-responses at least to the same levels as in sera drawn from the blood of patients recovering from the Corona virus, but in lower doses, according to Biontech CEO Ugur Shaheen.
Forty-five persons, aged between 18 and 55, participated in the experimental tests, the majority of whom received two doses with a difference of 21 days.
A published study on these experimental tests stated that a relatively large number of participants experienced a fever, but this is not surprising and does not constitute a stumbling block.
The vaccine works on the genetic code of the RNA device, which activates the production of cells by antibodies against the Corona virus.
There are a total of 23 projects on Covid-19 vaccines that have begun clinical trials in humans, according to the London University of Personal Hygiene and Tropical Medicine.
Many of these experimental vaccines were transferred to the second or third stage, which means that they were injected into thousands or even tens of thousands of volunteers.
Among the vaccines that are in the advanced stages of development are a coronavirus vaccine for the American company Biotechnology Moderna, and a vaccine for Oxford University in cooperation with the British Swedish AstraZeneca Foundation, as well as many Chinese projects.
Among the latter, an anti-coronavirus vaccine developed by Cansino Biotechnology Company, has been approved for use in the Chinese army.